A biotechnology company sought detailed product utilization data, by indication and line of therapy, and commercialization strategy support to help identify opportunities to improve access to its product. We leveraged our in-house claims data to assess the size and utilization patterns of the patient populations of interest, analyzing Part B claims data and translating analytic findings into actionable commercialization strategies (e.g., prioritization of target accounts based on factors such as patient volume, ownership affiliations, and changes in product market share). We developed visuals to convey the results of our analysis, which the client is using to better understand utilization trends and inform its growth strategy.

We used claims data to model the likely impacts of the Inflation Reduction Act (IRA) Part D drug pricing reforms on pipeline and portfolio products for a large life sciences manufacturer. Our Excel-based interactive tool enabled the client to assess impacts of Part D benefit redesign and Medicare drug price negotiation by estimating changes to manufacturer discount liability and net revenue for target products. The tool incorporated plan liability shifts associated with IRA policies, modeled how plans may change formulary management in response to increased liability, and determined resulting adjustments in manufacturer discretionary rebates that may be necessary to maintain beneficiary access and product market share. The model also reflected IRA impacts on patient out-of-pocket (OOP) costs and estimated how the Part D OOP cap may affect drug utilization. This work will inform the client’s risk mitigation, payer contracting, and patient access strategies for the coming years.

Offering an integrated suite of healthcare consulting and global policy, access, and value capabilities, we helped an emerging biotechnology company develop a multi-national pricing and commercialization strategy for a drug to treat an ultra-rare neurodegenerative disorder. The client sought our expertise in determining how payers in priority markets would assess the product’s value given clinical trial data (e.g., endpoints and patient groups), product characteristics, and market dynamics in each country of interest (i.e., US, EU, UK, Canada, Australia, and Japan). We reviewed published literature on the indication, conducted a coverage and reimbursement landscape analysis for each of the client’s target markets, and convened advisory board meetings among US and global payers to strengthen the client’s pricing and commercialization strategy.